The frequency of oxybate treatment dosing, driven by once-nightly dosing, was more than twice as important for overall product choice than the next two attributes, which were adverse reactions and sodium content, respectively.In the DCE, the frequency of oxybate treatment dosing was the most important driver for overall product choice, improved patient quality of life, and reduced patient anxiety and stress once-nightly dosing was preferred over twice-nightly.Clinicians (n=100) reported moderate to high satisfaction with immediate-release oxybate treatments however, clinicians indicated that twice-nightly dosing was a significant stressor for patients. ![]() Prior to the DCE, a survey to understand perspectives of first generation, twice-nightly oxybates, and other treatments for narcolepsy, was undertaken.Clinicians selected from hypothetical, randomly generated medicine profiles to determine which medication they preferred overall, which would improve patient quality of life, and which would reduce patient anxiety and stress. Decreased dosing frequency was the most important attribute when considering overall product choice, improving patient quality of life, and reducing their anxiety.”ĭiscrete choice experiments (DCE) are studies designed to characterize and quantify drivers of preferences for attributes. “The ability to further consolidate nocturnal sleep and simplify medication regimens is extraordinarily impactful. ![]() ![]() Data published recently demonstrate that clinicians recognize the negative impact of middle-of-the-night dosing required with twice-nightly therapies,” said Anne Marie Morse, D.O., Director of Child Neurology and Pediatric Sleep Medicine at Geisinger Medical Center at Janet Weis Children’s Hospital. “Sodium oxybate has been recognized as a standard of care to treat narcolepsy for more than 20 years, but, until recently, has required two nighttime doses for sufficient therapy. The paper, titled “Clinician Preferences for Oxybate Treatment for Narcolepsy: Survey and Discrete Choice Experiment,” was published in Advances in Therapy and can be accessed here. DUBLIN, Ireland, J(GLOBE NEWSWIRE) - Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced the publication of survey data describing clinician preferences among oxybate treatments for patients living with narcolepsy.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |